AYTUのチャート
AYTUの企業情報
| symbol | AYTU |
|---|---|
| 会社名 | Aytu BioScience Inc （アイトゥ・バイオサイエンス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Aytu BioScience Inc. is a commercial-stage healthcare company focused on acquiring developing and commercializing products in the field of urology. The Company focuses on hypogonadism prostate cancer urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide) a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company''s pipeline includes MiOXSYS an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone) a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company through its wholly-owned subsidiary Nuelle Inc. is focused on women’s sexual wellbeing and intimacy. アイトゥ・バイオサイエンスは米国のバイオ医薬品企業。泌尿器科の疾患に対する治療薬の開発・商業化に従事する。性腺機能低下症、泌尿器科のがん、男性不妊症、男性の健康における医療ニ―ズに焦点を置く。テストステロン製剤の鼻用ゲル「Natesto」、前立腺がん検出用の「ProstaScint」を開発する。本社所在地はコロラド州イ―グルウッド。 |
| 本社所在地 | 373 Inverness Parkway Suite 206 Englewood CO 80112 USA |
| 代表者氏名 | Joshua R. Disbrow ジョシュア・R・ディスブロー |
| 代表者役職名 | Chief Executive Officer Director 最高経営責任者（CEO） |
| 電話番号 | +1 720-437-6580 |
| 設立年月日 | 37469 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 63人 |
| url | www.aytubio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aytu |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.25294 |
| 終値（lastsale） | 1.19 |
| 時価総額（marketcap） | 2143679.09 |
| 時価総額 | 時価総額（百万ドル） 11.87358 |
| 売上高 | 売上高（百万ドル） 3.66012 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4.86105 |
| 当期純利益 | 当期純利益（百万ドル） -10.18786 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Aytu Bioscience Inc revenues increased 14% to $3.7M. Net loss decreased 55% to $10.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Derivative income increase from $213K to $4M (income) Interest (expense) decrease of 70% to $749K (expense). |
AYTUのテクニカル分析
AYTUのニュース
Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) 2023/03/06 12:40:52 Stock Equity
AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .
What You Absolutely Can’t Miss:: Aytu BioPharma, Inc. (NASDAQ:AYTU 0.77%), Guardion Health Sciences, Inc. (NASDAQ:GHSI -0.45%) 2023/02/25 13:11:28 Stock Equity
AYTU has seen its SMA50 which is now -25.96%. In looking the SMA 200 we see that the stock has seen a -57.53%. GHSI has seen its SMA50 which is … The post What You Absolutely Can’t Miss:: Aytu BioPharma, Inc. (NASDAQ:AYTU 0.77%), Guardion Health Sciences, Inc. (NASDAQ:GHSI -0.45%) appeared first on Stocks Equity .
Seducing stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU -5.78%), Gold Resource Corporation (AMEX:GORO -2.66%) 2023/02/24 13:45:46 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Seducing stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU -5.78%), Gold Resource Corporation (AMEX:GORO -2.66%) appeared first on Stocks Equity .
Aytu BioPharma''s Return On Capital Employed Insights 2023/02/22 14:48:36 Benzinga
Aytu BioPharma (NASDAQ: AYTU ) brought in sales totaling $26.28 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 854.78%, resulting in a loss of $6.69 million. Aytu BioPharma collected $27.66 million in revenue during Q1, but reported earnings showed a $701 thousand loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com
Aytu BioPharma, Inc. (AYTU) Q2 2023 Earnings Call Transcript 2023/02/22 02:35:05 Seeking Alpha
Aytu BioPharma, Inc. (NASDAQ:NASDAQ:AYTU) Q2 2023 Earnings Conference Call February 21, 2023 4:30 PM ETCompany ParticipantsRoger Weiss - Lytham PartnersJosh Disbrow - Chief Executive…
Aytu BioPharma, Inc.: Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference 2022/07/26 12:08:00 Finanz Nachrichten
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announc…
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference 2022/07/26 12:00:00 Wallstreet:Online
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Chief Executive Officer Josh Disbrow and …
Aytu BioPharma, Inc.: Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome 2022/07/20 12:08:00 Finanz Nachrichten
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiatio…
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome 2022/07/20 12:00:00 Wallstreet:Online
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of the global Phase 3 PREVEnt (Prevention of …
Aytu BioPharma Inc. (AYTU) Is Worth Thinking About For The Coming Weeks 2022/07/09 13:00:00 Stocks Register
Aytu BioPharma Inc. (NASDAQ:AYTU) price on Friday, July 08, fall -1.98% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.69. A look at the stock’s price movement, the close in the last trading session was $0.70, moving within a range at $0.67 and $0.6998. The beta value … Aytu BioPharma Inc. (AYTU) Is Worth Thinking About For The Coming Weeks Read More »
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company''s Board of Directors 2022/06/29 12:00:00 Wallstreet:Online
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company''s board of …
Can Aytu BioPharma Inc. (NASDAQ: AYTU) Still Be Considered A Loss When It’s Down -61.53% YTD? 2022/06/25 19:00:00 Marketing Sentinel
During the last session, Aytu BioPharma Inc. (NASDAQ:AYTU)’s traded shares were 0.58 million, with the beta value of the company hitting -0.10. At the end of the trading day, the stock’s price was $0.52, reflecting an intraday loss of -0.54% or $0.0. The 52-week high for the AYTU share is $5.70, that puts it down … Can Aytu BioPharma Inc. (NASDAQ: AYTU) Still Be Considered A Loss When It’s Down -61.53% YTD? Read More »
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference 2022/06/13 12:00:00 Wallstreet:Online
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners …
Aytu BioPharma Plans To Divest / Discontinue Non Core Assets 2022/05/17 11:29:46 Benzinga
Aytu BioPharma Inc (NASDAQ: AYTU ) will divest or discontinue non-core, unprofitable products, including Cefaclor, Flexichamber, Tuzistra XR, generic Tussionex, and Zolpimist. Aytu expects to improve gross margins for its ADHD product franchise by transferring manufacturing to a … Full story available on Benzinga.com